In March 2020, the World Health Organization (WHO) launched a major clinical trial to study the effectiveness of 4 antiviral drugs in treating patients in the hospital with COVID-19. The study drugs were: Remdesivir, Hydroxychloroquine, Lopinavir and Interferon-β1a. The trial allowed researchers to stop drugs that they thought were not working, and replace them with newer ones. The research took place in 405 hospitals across 30 countries with 11,266 adult patients. Did any of the drugs lower the death rate of hospitalized patients with COVID-19? No. Overall, none of the drugs reduced death rates, the need for a ventilator, or the length of stay in the hospital. These results suggest that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no beneficial effect for patients hospitalized with COVID-19. Already, newer treatments are available as we await a vaccine.